Text Size




Home | Clinical Trials

FDA Approved Drugs » 1996
Medical Areas: Cardiology/Vascular Diseases | Gastroenterology | Hematology | Nephrology | Neurology | Oncology | Pulmonary/Respiratory Diseases

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Visipaque (iodixanol)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Nycomed
Approval Status: Approved April 1996
Treatment Area: diagnosis of disease in major organs

General Information

Visipaque is a contrast agent that allows doctors to better diagnose diseases of the heart, brain, kidney, blood vessels and other major organs.

Additional Information

Contrast agents, in general, are fluids that are injected into a subject's blood stream to enhance the images, or pictures, of certain body organ structures or processes obtained during diagnostic imaging procedures. This enhancement enables physicians to more accurately detect, diagnose, and properly treat disease, states, and functional abnormalities, such as tumors and cardiovascular disorders.

Each year, as many as 18 million subjects in the United States undergo X-rays and other diagnostic procedures that require the administration of contrast media to aid in the detailed visualization of internal organs and tissues.

 Back to Top | Printer Friendly Version

Get Involved

Stroke and You

Our Mission Statement

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.

National Stroke Association

9707 E. Easter Lane, Suite B
Centennial, CO 80112